Abstract
What is NGS? Basically, we give this name to a group of technologies that allow the sequencing of thousands or millions of DNA or RNA fragments in parallel, while with the Sanger methods we were amplifying and evaluating those fragments one by one. The result is an enormous increase in the sequencing capacity and speed, and a huge decrease in the cost per sequence. As an example, one of the currently available NGS machines is able to perform the same work as 100,000 Sanger sequencers. In the “Sanger Sequencing era” we had to focus our analysis in a limited number of fragments or genes, and the cost of the studies was a major determinant in the decision to perform genetic studies in patients affected by inherited diseases. Now, we can use the huge capacity of the NGS technologies to perform not only more comprehensive studies, but also cheaper ones. NGS is very useful for the evaluation of many genes, or even a whole genome, in individual patients. It is also very appropriate for the evaluation of lower numbers of genes in multiple patients at the same time, which is very important to increase the accessibility to the genetic tests.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Monserrat L, Ortiz-Genga M, Lesende I, Garcia-Giustiniani D, Barriales-Villa R, de Una-Iglesias D, et al. Genetics of cardiomyopathies: novel perspectives with next generation sequencing. Curr Pharm Des. 2015;21(4):418–30.
Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European heart rhythm association (EHRA). Europace. 2011;13(8):1077–109.
Cuenca S, Ruiz-Cano MJ, Gimeno-Blanes JR, Jurado A, Salas C, Gomez-Diaz I, et al. Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. J Heart Lung Transplant. 2016;35(5):625–35.
Poptsova MS, Il'icheva IA, Nechipurenko DY, Panchenko LA, Khodikov MV, Oparina NY, et al. Non-random DNA fragmentation in next-generation sequencing. Sci Rep. 2014;4:4532.
Ion Semiconductor Sequencing. In Wikipedia, the free encyclopedia. 2017. Retrieved 02 July 2017, from https://en.wikipedia.org/w/index.php?title=Ion_semiconductor_sequencing&oldid=780682285.
Illumina Dye Sequencing. In Wikipedia, The Free Encyclopedia. 2017. Retrieved 02 July 2017, from https://en.wikipedia.org/w/index.php?title=Illumina_dye_sequencing&oldid=776525060.
Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285–91.
Monserrat L, Mazzanti A, Ortiz-Genga M, Barriales-Villa R, Garcia D, Gimeno-Blanes JR. The interpretation of genetic tests in inherited cardiovascular diseases. Cardiogenetics. 2011;1:e8.
Li H, Chen D, Zhang J. Analysis of intron sequence features associated with transcriptional regulation in human genes. PLoS One. 2012;7(10):e46784.
Makita N, Behr E, Shimizu W, Horie M, Sunami A, Crotti L, et al. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest. 2008;118(6):2219–29.
Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366:619–28.
Ortiz-Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado-Aranda R, et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll Cardiol. 2016;68(22):2440–51.
García-Giustiniani D, Arad M, Ortíz-Genga M, Barriales-Villa R, Fernández X, Rodríguez-García I, et al. Phenotype and prognostic correlations of the converter region mutations affecting the β myosin heavy chain. Heart. 2015;101(13):1047–53.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Monserrat, L. (2018). Genetic and Genomic Technologies: Next Generation Sequencing for Inherited Cardiovascular Conditions. In: Kumar, D., Elliott, P. (eds) Cardiovascular Genetics and Genomics. Springer, Cham. https://doi.org/10.1007/978-3-319-66114-8_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-66114-8_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-66112-4
Online ISBN: 978-3-319-66114-8
eBook Packages: MedicineMedicine (R0)